Antibe Therapeutics

03/27/2024

Primary market research with U.S. clinicians confirms high unmet need for safer non-opioid medications for acute pain.

$ATE.TO $ATBPF

03/20/2024

Read the our latest press release here: https://loom.ly/NA7-tLE

$ATE.TO $ATBPF

03/14/2024

To reduce opioid use, widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) in multimodal analgesia strategies has become standard of care -- otenaproxesul is a next-generation NSAID.

$ATE.TO $ATBPF

03/08/2024

Read our latest press release here: https://loom.ly/YY6GvCE

$ATE.TO $ATBPF

02/27/2024

“With widespread concerns about opioid misuse and addiction, there’s a notable shift towards prioritizing the creation of safer, non-addictive alternatives.”

To read the full Labiotech article featuring Antibe's Chief Medical Officer, Dr. Joe Stauffer, visit labiotech.eu/in-depth/new-non-opioid-pain-medication/.

$ATE.TO $ATBPF

Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis.

02/23/2024

Beginning with a commercial focus on post-operative pain, we plan to rapidly expand into other acute areas, including acute musculoskeletal pain, dysmenorrhea, migraine, gout, and dental pain.

$ATE.TO $ATBPF

02/20/2024

Positioned as the non-opioid of choice for acute pain, otenaproxesul is headed into its Phase II trial next month – addressing a US $25+ billion market with no novel drugs introduced in 25 years...

$ATE.TO $ATBPF

02/15/2024

Read the our latest press release here: antibethera.com/news/antibe-reports-q3-2024-interim-financial-and-operating-results

$ATE.TO $ATBPF

02/09/2024

$ATE.TO $ATBPF

02/06/2024

The research on hydrogen sulfide's therapeutic potential keeps growing... for the latest on its cardioprotective effects, see this recent paper in Cells: mdpi.com/2073-4409/13/2/158

$ATE.TO $ATBPF

02/01/2024